Literature DB >> 16533586

Stability and degradation kinetics of meropenem in powder for injection and reconstituted sample.

Andreas S L Mendez1, Jean Dalomo, Martin Steppe, Elfrides E S Schapoval.   

Abstract

The stability of broad-spectrum antibiotic meropenem was studied in order to investigate the kinetics of degradation of this drug in powder for injection and reconstituted sample. Carbapenem was submitted to conditions of accelerated thermal decomposition. Degradation of meropenem was adequately modeled by specific equations for order rate kinetics. The analyses of the degraded samples were performed by high-performance liquid chromatographic (HPLC) method and microbiological assay. At higher temperatures, the decomposition reactions of meropenem in powder for injection could be described by first-order kinetics. The higher rate of degradation was observed in meropenem reconstituted in 0.9% sodium chloride, and the thermal decomposition obeyed also first-order kinetics. The results obtained confirm the reliability of chromatographic method for determining the kinetics run of meropenem in the presence of its degradation products. The present study reveals the thermal lability of the drug, especially as reconstituted sample. Thus, appropriate thermal protection is recommended during the storage and handling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16533586     DOI: 10.1016/j.jpba.2006.02.017

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  8 in total

1.  Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo.

Authors:  Kathleen England; Helena I M Boshoff; Kriti Arora; Danielle Weiner; Emmanuel Dayao; Daniel Schimel; Laura E Via; Clifton E Barry
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

2.  In Vitro Stabilifighty Evaluation of Different Pharmaceutical Products Containing Meropenem.

Authors:  Cristina Tomasello; Anna Leggieri; Roberta Cavalli; Giovanni Di Perri; Antonio D'Avolio
Journal:  Hosp Pharm       Date:  2015-04-08

3.  Reply to Béranger et al., "Integration of Continuous Renal Replacement Therapy in a Meropenem Population Pharmacokinetics Model in Critically Ill Children".

Authors:  Jumpei Saito; Kensuke Shoji; Yusuke Oho; Hiroki Kato; Shotaro Matsumoto; Satoshi Aoki; Hidefumi Nakamura; Takanori Ogawa; Mayumi Hasegawa; Akimasa Yamatani; Isao Miyairi
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

4.  Stability, compatibility and microbiological activity studies of meropenem-clavulanate potassium.

Authors:  Judyta Cielecka-Piontek; Daria Szymanowska-Powałowska; Magdalena Paczkowska; Piotr Łysakowski; Przemysław Zalewski; Piotr Garbacki
Journal:  J Antibiot (Tokyo)       Date:  2014-07-30       Impact factor: 2.649

Review 5.  Evaluation of evidence for pharmacokinetics-pharmacodynamics-based dose optimization of antimicrobials for treating Gram-negative infections in neonates.

Authors:  Nusrat Shafiq; Samir Malhotra; Vikas Gautam; Harpreet Kaur; Pravin Kumar; Sourabh Dutta; Pallab Ray; Nilima A Kshirsagar
Journal:  Indian J Med Res       Date:  2017-03       Impact factor: 2.375

6.  An investigation of the stability of meropenem in elastomeric infusion devices.

Authors:  Finbarr Foy; Giuseppe Luna; Jorge Martinez; Zach Nizich; Jason Seet; Katie Lie; Bruce Sunderland; Petra Czarniak
Journal:  Drug Des Devel Ther       Date:  2019-08-01       Impact factor: 4.162

7.  Elution and Biomechanical Properties of Meropenem-Loaded Bone Cement.

Authors:  Li-Hong Wang; Ya-Dong Feng; Xiao-Wei Zhang; Long Jin; Fang-Lun Zhou; Guo-Hong Xu
Journal:  Orthop Surg       Date:  2021-11-03       Impact factor: 2.071

8.  A Natural Deep Eutectic Solvent Formulated to Stabilize β-Lactam Antibiotics.

Authors:  Belén Olivares; Fabián Martínez; Lina Rivas; Cristian Calderón; José M Munita; Paola R Campodonico
Journal:  Sci Rep       Date:  2018-10-08       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.